Palisade Bio (PALI) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.04% |
| Dec 31, 2025 | -18.66% |
| Sep 30, 2025 | -9.25% |
| Jun 30, 2025 | -8.51% |
| Mar 31, 2025 | -2.41% |
| Dec 31, 2024 | -9.77% |
| Sep 30, 2024 | -10.56% |
| Jun 30, 2024 | -16.42% |
| Mar 31, 2024 | -7.74% |
| Dec 31, 2023 | -12.09% |
| Sep 30, 2023 | -12.87% |
| Jun 30, 2023 | -11.10% |
| Mar 31, 2023 | -0.06% |
| Dec 31, 2022 | -11.30% |
| Sep 30, 2022 | -11.43% |
| Jun 30, 2022 | 11.09% |
| Mar 31, 2022 | 2.21% |
| Dec 31, 2021 | 25.09% |
| Sep 30, 2021 | 24.54% |
| Jun 30, 2021 | -50.27% |
| Mar 31, 2021 | 11.14% |
| Dec 31, 2020 | 2.33% |
| Sep 30, 2020 | 20.04% |
| Jun 30, 2020 | 19.39% |
| Mar 31, 2020 | 17.09% |
| Dec 31, 2019 | 15.93% |
| Sep 30, 2019 | 13.88% |
| Jun 30, 2019 | 13.28% |
| Mar 31, 2019 | 15.34% |
| Dec 31, 2018 | 11.01% |
| Sep 30, 2018 | 12.65% |
| Jun 30, 2018 | 11.34% |
| Mar 31, 2018 | 4.45% |
| Dec 31, 2017 | 3.65% |
| Sep 30, 2017 | 0.05% |
| Jun 30, 2017 | -12.17% |
| Mar 31, 2017 | -12.12% |
| Dec 31, 2016 | -17.91% |
| Sep 30, 2016 | -9.86% |
| Jun 30, 2016 | -2.57% |
| Mar 31, 2016 | -13.47% |
| Dec 31, 2015 | -25.75% |
| Sep 30, 2015 | -7.61% |
| Jun 30, 2015 | -5.37% |